var data={"title":"Supraventricular arrhythmias during pregnancy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Supraventricular arrhythmias during pregnancy</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/contributors\" class=\"contributor contributor_credentials\">Candice Silversides, MD, MS, FRCPC</a></dd><dd><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/contributors\" class=\"contributor contributor_credentials\">Louise Harris, MBChB</a></dd><dd><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/contributors\" class=\"contributor contributor_credentials\">Sing-Chien Yap, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/contributors\" class=\"contributor contributor_credentials\">Hugh Calkins, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/contributors\" class=\"contributor contributor_credentials\">N A Mark Estes, III, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/contributors\" class=\"contributor contributor_credentials\">Brian C Downey, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 04, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H11407702\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Arrhythmias are the most common cardiac complication encountered during pregnancy in women with and without structural heart disease [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Arrhythmias may manifest for the first time during pregnancy, and in other cases, pregnancy can trigger exacerbations in women with pre-existing arrhythmias [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/1,4-6\" class=\"abstract_t\">1,4-6</a>]. Women with established arrhythmias or structural heart disease are at highest risk of developing arrhythmias during pregnancy. In addition, there has been an increase in the number of women of childbearing age with congenital heart disease (due to surgical advances), and these women are at particularly high risk for arrhythmias (<a href=\"image.htm?imageKey=CARD%2F61986\" class=\"graphic graphic_figure graphicRef61986 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/1,2,7-11\" class=\"abstract_t\">1,2,7-11</a>]. Because of these associations, any woman who presents with an arrhythmia should have a clinical evaluation with a complete history and cardiac examination, an electrocardiogram, and a transthoracic echocardiogram to evaluate for evidence of structural heart disease.</p><p>In general, the approach to the treatment of arrhythmias in pregnancy is similar to that in the nonpregnant patient. However, due to the theoretical or known adverse effects of antiarrhythmic drugs on the fetus, antiarrhythmic drugs are often reserved for the treatment of arrhythmias associated with clinically significant symptoms or hemodynamic compromise [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/12-14\" class=\"abstract_t\">12-14</a>]. Treatment recommendations are hampered by the lack of randomized trials and very little or no data on efficacy or safety of antiarrhythmic drugs during pregnancy. Choice of therapy, for the most part, is based on limited data from animal studies, case reports, and observational studies, as well as clinical experience.</p><p>The prevalence, clinical presentation, and management of supraventricular arrhythmias during pregnancy will be reviewed. Electrocardiographic characteristics of supraventricular arrhythmias, as well as issues relating to conduction disorders, ventricular arrhythmias, and cardiac arrest during pregnancy, are discussed separately. (See <a href=\"topic.htm?path=ecg-tutorial-atrial-and-atrioventricular-nodal-supraventricular-arrhythmias\" class=\"medical medical_review\">&quot;ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias&quot;</a> and <a href=\"topic.htm?path=maternal-conduction-disorders-and-bradycardia-during-pregnancy\" class=\"medical medical_review\">&quot;Maternal conduction disorders and bradycardia during pregnancy&quot;</a> and <a href=\"topic.htm?path=ventricular-arrhythmias-during-pregnancy\" class=\"medical medical_review\">&quot;Ventricular arrhythmias during pregnancy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11407709\"><span class=\"h1\">MECHANISM OF ARRHYTHMOGENESIS IN PREGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The exact mechanism of increased arrhythmia burden during pregnancy is unclear, but has been attributed to hemodynamic, hormonal, and autonomic changes related to pregnancy.</p><p>The hemodynamic changes of pregnancy have been well studied, and a number of these changes likely contributes to the development of arrhythmias during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/15,16\" class=\"abstract_t\">15,16</a>]. (See <a href=\"topic.htm?path=maternal-adaptations-to-pregnancy-cardiovascular-and-hemodynamic-changes\" class=\"medical medical_review\">&quot;Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes&quot;</a>.)</p><p>Intravascular volume increases, augmenting the preload on the ventricles and increasing both atrial and ventricular size [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/15,17-20\" class=\"abstract_t\">15,17-20</a>]. Atrial and ventricular myocardial stretch may contribute to arrhythmogenesis, due to stretch-activated ion channel activity causing membrane depolarization, shortened refractoriness, slowed conduction, and spatial dispersion of refractoriness and conduction [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/21-24\" class=\"abstract_t\">21-24</a>]. There is also an increase in resting heart rate, which has been associated with markers of arrhythmogenesis such as late potentials, premature ventricular contractions, and depressed heart rate variability [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/25\" class=\"abstract_t\">25</a>]. </p><p>Few studies have been published on the influence of hormonal and autonomic changes on arrhythmogenesis in pregnancy. Although catecholamine levels do not appear to change during pregnancy, there is an increase in adrenergic responsiveness during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/26-30\" class=\"abstract_t\">26-30</a>]. Estrogen has been shown to increase the number of myocardial alpha-adrenergic receptors [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/31\" class=\"abstract_t\">31</a>]. This increased adrenergic activity may contribute to enhanced automaticity and triggered activity [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/32\" class=\"abstract_t\">32</a>]. </p><p class=\"headingAnchor\" id=\"H11407716\"><span class=\"h1\">PALPITATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. The differential diagnosis of palpitations is extensive and the diagnostic evaluation of pregnant women with palpitations does not differ from nonpregnant women. (See <a href=\"topic.htm?path=overview-of-palpitations-in-adults\" class=\"medical medical_review\">&quot;Overview of palpitations in adults&quot;</a>.)</p><p>One study compared 110 pregnant women with symptoms suggestive of possible arrhythmia (palpitations: 87 percent; dizziness: 13 percent; <span class=\"nowrap\">syncope/presyncope:</span> 6 percent) with 52 pregnant women evaluated for a functional murmur [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/33\" class=\"abstract_t\">33</a>]. Prevalence of supraventricular and ventricular ectopic activity on 24-hour Holter ambulatory monitoring was similar in the symptomatic and control groups. </p><p>Only 10 percent of symptomatic episodes were accompanied by the presence of arrhythmias. A sensation of palpitations during pregnancy, in the absence of concomitant cardiac arrhythmias, may be related to the high output state, including increased heart rate, decreased peripheral resistance, and increased stroke volumes. (See <a href=\"topic.htm?path=maternal-adaptations-to-pregnancy-cardiovascular-and-hemodynamic-changes\" class=\"medical medical_review\">&quot;Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11407723\"><span class=\"h1\">ATRIAL PREMATURE BEATS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atrial premature beats (APBs) are very frequent in pregnant women and the prevalence is dependent on the duration of observation. (See <a href=\"topic.htm?path=supraventricular-premature-beats\" class=\"medical medical_review\">&quot;Supraventricular premature beats&quot;</a>.)</p><p>In one study of 162 pregnancies in women with structurally normal hearts evaluated with 24-hour Holter monitoring, the prevalence of APBs was 57 percent and frequent APBs (&gt;100 APBs per 24 hours) occurred in six percent of pregnancies [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/33\" class=\"abstract_t\">33</a>]. There was a significant reduction in the frequency of atrial and ventricular ectopic activity in nine women in whom Holter monitoring was repeated postpartum.</p><p class=\"headingAnchor\" id=\"H11407730\"><span class=\"h2\">Clinical presentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>APBs produce few or no symptoms in the majority of women, although some women may have symptoms of palpitations. </p><p class=\"headingAnchor\" id=\"H11407737\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No therapy is required for APBs in the asymptomatic woman. Pregnant women with symptomatic APBs should be reassured of the benign nature of APBs and be advised to discontinue potential precipitant factors such as smoking, coffee intake, alcohol intake, or other stimulants [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13\" class=\"abstract_t\">13</a>].</p><p>If ectopic activity continues and is associated with intolerable symptoms, treatment with cardioselective beta blockers such as <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a> can be effective. (See <a href=\"#H11407891\" class=\"local\">'Issues regarding antiarrhythmic drug treatment'</a> below.)</p><p class=\"headingAnchor\" id=\"H11407744\"><span class=\"h1\">PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Paroxysmal supraventricular tachycardia (PSVT) describes a tachycardia that is caused, in the vast majority of patients, either by reentry within the atrioventricular (AV) node or by use of an accessory pathway, either overt or concealed. (See <a href=\"topic.htm?path=atrioventricular-nodal-reentrant-tachycardia\" class=\"medical medical_review\">&quot;Atrioventricular nodal reentrant tachycardia&quot;</a>.)</p><p>In women with structurally normal hearts, AV nodal reentrant tachycardia (AVNRT) is the most common PSVT, followed by AV reciprocating tachycardia (AVRT) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/4\" class=\"abstract_t\">4</a>]. In one single center study, the prevalence of PSVT has been estimated at 24 per 100,000 hospital admissions in pregnant women [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/34\" class=\"abstract_t\">34</a>].</p><p>There are discrepancies between studies as to whether pregnancy increases the risk of first onset of PSVT [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/4,35\" class=\"abstract_t\">4,35</a>]. One study of 38 women with PSVT and a previous pregnancy found that the initial onset of PSVT occurred during pregnancy in 13 women (34 percent). The estimated relative risk of first onset of PSVT during pregnancy was 5.1 (95 percent confidence interval 2.8 to 9.2) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/35\" class=\"abstract_t\">35</a>]. In contrast, another study of 173 women with symptomatic PSVT and a history of pregnancy referred for electrophysiologic testing and radiofrequency catheter ablation, reported that only 4.6 percent had initial onset of PSVT during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/4\" class=\"abstract_t\">4</a>]. In that series, pregnancy was not associated with first onset of PSVT. Furthermore, in women with AVNRT there was a decreased risk of first onset of AVNRT during pregnancy (relative risk 0.11, 95% CI 0.02-0.56).</p><p>The same study found that among women with a first onset of PSVT before pregnancy, the majority (85 percent) of women had an exacerbation of PSVT during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/4\" class=\"abstract_t\">4</a>]. Exacerbations of PSVT during pregnancy were more symptomatic (assessed by a semiquantitative questionnaire) when compared with arrhythmias during nonpregnant periods.</p><p class=\"headingAnchor\" id=\"H11407751\"><span class=\"h2\">Clinical presentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presentation of PSVT during pregnancy is the same as in the nonpregnant state and includes symptoms of palpitations that may be associated with presyncope, syncope, dyspnea, <span class=\"nowrap\">and/or</span> chest pain. Patients with PSVT typically describe a regular and rapid tachycardia of abrupt onset, with or without abrupt termination. The clinical and hemodynamic consequences of the arrhythmia depend on many variables including the presence or absence of structural heart disease. For example, in women with Ebstein&rsquo;s anomaly of the tricuspid valve, symptomatic AVRT episodes can result in serious hemodynamic deterioration [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14,36\" class=\"abstract_t\">14,36</a>]. PSVT is usually well tolerated in women without structural heart disease [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/5,37-45\" class=\"abstract_t\">5,37-45</a>].</p><p class=\"headingAnchor\" id=\"H2955272064\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We agree with the recommendations for pregnant women made in the 2015 American College of <span class=\"nowrap\">Cardiology/American</span> Heart <span class=\"nowrap\">Association/Heart</span> Rhythm Society guidelines for the management of adult patients with supraventricular tachycardia [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/46\" class=\"abstract_t\">46</a>].</p><p class=\"headingAnchor\" id=\"H11407758\"><span class=\"h2\">Management of acute episodes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If hemodynamic compromise is evident, direct-current cardioversion should be performed. (See <a href=\"topic.htm?path=cardioversion-for-specific-arrhythmias\" class=\"medical medical_review\">&quot;Cardioversion for specific arrhythmias&quot;</a> and <a href=\"topic.htm?path=basic-principles-and-technique-of-electrical-cardioversion-and-defibrillation\" class=\"medical medical_review\">&quot;Basic principles and technique of electrical cardioversion and defibrillation&quot;</a> and <a href=\"topic.htm?path=cardioversion-for-specific-arrhythmias#H18\" class=\"medical medical_review\">&quot;Cardioversion for specific arrhythmias&quot;, section on 'Cardioversion during pregnancy'</a>.)</p><p>When the patient is hemodynamically stable, acute episodes of PSVT may be terminated by transiently blocking AV nodal conduction. If vagal maneuvers (eg, Valsalva maneuver or carotid sinus massage) fail, intravenous <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a> (6 to 12 mg) is an appropriate choice in pregnancy, terminating approximately 90 percent of PSVT [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/47\" class=\"abstract_t\">47</a>]. Case reports have demonstrated the effectiveness of adenosine in pregnant women, although in most of the reports adenosine was administrated in the second and third trimester [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/48-52\" class=\"abstract_t\">48-52</a>]. (See <a href=\"topic.htm?path=atrioventricular-nodal-reentrant-tachycardia#H21\" class=\"medical medical_review\">&quot;Atrioventricular nodal reentrant tachycardia&quot;, section on 'Initial management'</a>.)</p><p><a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">Adenosine</a> has a very short half-life (&lt;10 seconds) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/53\" class=\"abstract_t\">53</a>], reducing the placental exposure to adenosine [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/54\" class=\"abstract_t\">54</a>]. Despite reduced adenosine deaminase activity during pregnancy (25 percent) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/55\" class=\"abstract_t\">55</a>], the adenosine dose required for PSVT termination during pregnancy is not reduced, possibly due to the increased volume of distribution [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/56\" class=\"abstract_t\">56</a>]. (See <a href=\"#H11407891\" class=\"local\">'Issues regarding antiarrhythmic drug treatment'</a> below.)</p><p>Recommended second-line drugs are intravenous beta-adrenergic blockers such as <a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a> and <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a> [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/11,14\" class=\"abstract_t\">11,14</a>]. The experience with intravenous <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a> is limited [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/57\" class=\"abstract_t\">57</a>] and the longer half-life (5.3 hours) of verapamil can cause significant hypotension, especially when given as a rapid intravenous bolus injection [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"#H11407891\" class=\"local\">'Issues regarding antiarrhythmic drug treatment'</a> below.)</p><p class=\"headingAnchor\" id=\"H11407765\"><span class=\"h2\">Prophylactic pharmacologic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prevention of PSVT can be accomplished with a number of AV nodal blocking agents (ie, <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a> or beta blockers) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"#H11407891\" class=\"local\">'Issues regarding antiarrhythmic drug treatment'</a> below and <a href=\"topic.htm?path=atrioventricular-nodal-reentrant-tachycardia#H26\" class=\"medical medical_review\">&quot;Atrioventricular nodal reentrant tachycardia&quot;, section on 'Preventive therapy'</a>.)</p><p>Experience with <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a> is extensive and it is considered safe during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13,58\" class=\"abstract_t\">13,58</a>]. However, the efficacy of digoxin for prophylaxis has not been demonstrated. One small, randomized, cross-over study of 11 nonpregnant patients showed that there was similar efficacy between digoxin, <a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a>, and <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a> with respect to the frequency or duration of PSVT [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/59\" class=\"abstract_t\">59</a>]. Propranolol and <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a> are often used, but the potential fetal risks of beta blockers need to be discussed with the mother, in particular the risk of intra-uterine growth restriction [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/60-64\" class=\"abstract_t\">60-64</a>] (see <a href=\"#H11407891\" class=\"local\">'Issues regarding antiarrhythmic drug treatment'</a> below). <a href=\"topic.htm?path=atenolol-drug-information\" class=\"drug drug_general\">Atenolol</a> should not be used for treatment of arrhythmias. Other options include <a href=\"topic.htm?path=sotalol-drug-information\" class=\"drug drug_general\">sotalol</a> or <a href=\"topic.htm?path=flecainide-drug-information\" class=\"drug drug_general\">flecainide</a> [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Combination therapy is sometimes used for women with significant symptomatic episodes. A combination of type IA antiarrhythmic drug (eg, <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a>, <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a>) and <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a> for women with concealed accessory pathway, or beta blocker and digoxin for women with AVNRT, has been used during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13\" class=\"abstract_t\">13</a>]. Type IA antiarrhythmic drugs slow the conduction of the accessory pathway. </p><p>For symptomatic women with drug-refractory arrhythmias, radiofrequency catheter ablation of the accessory or slow pathway should be considered prior to pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/11\" class=\"abstract_t\">11</a>]. In women with malignant, drug-resistant arrhythmias, radiofrequency catheter ablation during pregnancy may be an option in selected cases [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/65\" class=\"abstract_t\">65</a>]. (See <a href=\"#H11407940\" class=\"local\">'Radiofrequency catheter ablation'</a> below and <a href=\"topic.htm?path=atrioventricular-nodal-reentrant-tachycardia\" class=\"medical medical_review\">&quot;Atrioventricular nodal reentrant tachycardia&quot;</a>.)</p><p>In general, anticoagulation therapy is not indicated for SVT such as AVNRT, AVRT over a bypass tract, or ectopic atrial tachycardia.</p><p class=\"headingAnchor\" id=\"H11407772\"><span class=\"h1\">FOCAL ATRIAL TACHYCARDIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Focal atrial tachycardia is relatively rare during pregnancy. (See <a href=\"topic.htm?path=focal-atrial-tachycardia\" class=\"medical medical_review\">&quot;Focal atrial tachycardia&quot;</a>.)</p><p>Although this arrhythmia is often associated with structural heart disease in nonpregnant women, most reports of atrial tachycardia during pregnancy have been reported in women without apparent structural heart disease [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/5,42-45,66\" class=\"abstract_t\">5,42-45,66</a>].</p><p class=\"headingAnchor\" id=\"H11407779\"><span class=\"h2\">Clinical presentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As in the nonpregnant state, this arrhythmia is often persistent and can be refractory to treatment, including direct current (DC) cardioversion [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/5,42-45,66\" class=\"abstract_t\">5,42-45,66</a>]. Because many atrial tachycardias are caused by enhanced automaticity, vagal maneuvers or the use of antiarrhythmic agents that decrease atrioventricular nodal conduction (eg, <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a>, <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a>, beta blockers, calcium channel blockers), will usually not terminate the arrhythmia [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/5,42,43\" class=\"abstract_t\">5,42,43</a>]. </p><p>In most reported cases, the arrhythmia subsides and terminates shortly after delivery, suggesting that pregnancy may contribute to the initiation and maintenance of this tachyarrhythmia [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/5,42-45,66\" class=\"abstract_t\">5,42-45,66</a>]. </p><p class=\"headingAnchor\" id=\"H11407786\"><span class=\"h2\">Diagnosis and management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differentiation between atrial tachycardia and other supraventricular tachyarrhythmias may be difficult. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-evaluation-of-narrow-qrs-complex-tachycardias\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias&quot;</a>.)</p><p>The administration of <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a> may be useful as a therapeutic and diagnostic tool. Because atrial tachycardia is difficult to treat and is generally well tolerated by the mother and the fetus, urgent DC cardioversion or administration of multiple intravenous drugs is not recommended when pregnant women are hemodynamically stable. </p><p>The goal of therapy should be to achieve adequate rate control. The risk of not treating an incessant atrial tachycardia is the development of a tachycardia-induced cardiomyopathy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/67\" class=\"abstract_t\">67</a>]. (See <a href=\"topic.htm?path=arrhythmia-induced-cardiomyopathy\" class=\"medical medical_review\">&quot;Arrhythmia-induced cardiomyopathy&quot;</a>.)</p><p>Rate control can be achieved with <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a>, beta blockers, or calcium channel blockers (eg, <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/5,42,43\" class=\"abstract_t\">5,42,43</a>], with reservation of <a href=\"topic.htm?path=sotalol-drug-information\" class=\"drug drug_general\">sotalol</a>, <a href=\"topic.htm?path=flecainide-drug-information\" class=\"drug drug_general\">flecainide</a>, or <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a> (in very rare cases due to potential toxicity) for refractory cases (<a href=\"image.htm?imageKey=CARD%2F50716\" class=\"graphic graphic_table graphicRef50716 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/43,68\" class=\"abstract_t\">43,68</a>]. Decisions regarding the use of other antiarrhythmic drugs should be made with the assistance of an electrophysiologist. </p><p>For women with hemodynamically significant atrial tachycardia with a rapid ventricular response who do not respond to medical therapy and do not have a reversible precipitating cause, DC cardioversion may be required. However, as noted above, atrial tachycardias may be particularly resistant to cardioversion. (See <a href=\"topic.htm?path=cardioversion-for-specific-arrhythmias#H18\" class=\"medical medical_review\">&quot;Cardioversion for specific arrhythmias&quot;, section on 'Cardioversion during pregnancy'</a> and <a href=\"#H11407933\" class=\"local\">'Electrical cardioversion'</a> below.)</p><p>In some women with incessant atrial tachycardia, radiofrequency catheter ablation may need to be considered [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/65,69\" class=\"abstract_t\">65,69</a>]. (See <a href=\"#H11407940\" class=\"local\">'Radiofrequency catheter ablation'</a> below and <a href=\"topic.htm?path=focal-atrial-tachycardia\" class=\"medical medical_review\">&quot;Focal atrial tachycardia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11407793\"><span class=\"h1\">ATRIAL FIBRILLATION AND FLUTTER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atrial fibrillation and flutter during pregnancy are less common than paroxysmal supraventricular tachycardia. In one single center study, the prevalence of atrial fibrillation and flutter was 2 in 100,000 hospital admissions in pregnant women [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/34\" class=\"abstract_t\">34</a>]. These arrhythmias can occur in women with structurally normal hearts [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/70,71\" class=\"abstract_t\">70,71</a>]; however, they are more common in women with structural heart disease, such as rheumatic heart disease [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/72\" class=\"abstract_t\">72</a>], valvular heart disease [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/73\" class=\"abstract_t\">73</a>], hypertrophic cardiomyopathy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/74\" class=\"abstract_t\">74</a>], peripartum cardiomyopathy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/75\" class=\"abstract_t\">75</a>], and congenital heart disease [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/6,37,76-79\" class=\"abstract_t\">6,37,76-79</a>]. (See <a href=\"topic.htm?path=epidemiology-of-and-risk-factors-for-atrial-fibrillation\" class=\"medical medical_review\">&quot;Epidemiology of and risk factors for atrial fibrillation&quot;</a> and <a href=\"topic.htm?path=overview-of-atrial-flutter\" class=\"medical medical_review\">&quot;Overview of atrial flutter&quot;</a>.)</p><p>Metabolic disturbances such as hyperthyroidism [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/37\" class=\"abstract_t\">37</a>] and electrolyte imbalances can also contribute to the development of atrial fibrillation during pregnancy and should be checked at the time of presentation. </p><p class=\"headingAnchor\" id=\"H11407800\"><span class=\"h2\">Clinical presentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical presentation and hemodynamic consequences of atrial fibrillation and flutter depend on many variables including the underlying heart condition and the associated ventricular response rate. In women with rheumatic or congenital heart disease, pre-existing heart failure, or a rapidly conducting antegrade accessory pathway, atrial fibrillation and flutter may have serious hemodynamic consequences [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/73,76-78,80\" class=\"abstract_t\">73,76-78,80</a>]. For example, women with significant mitral stenosis are dependent on the diastolic filling time and the atrial systolic contribution for adequate left ventricular filling; these women tolerate atrial fibrillation poorly and can develop concomitant pulmonary edema due to rise in left atrial pressure [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/81\" class=\"abstract_t\">81</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-rheumatic-mitral-stenosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of rheumatic mitral stenosis&quot;</a>.)</p><p>Besides the hemodynamic consequences, pregnant women with atrial fibrillation are at increased risk of systemic embolism [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/37\" class=\"abstract_t\">37</a>]. (See <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11407807\"><span class=\"h2\">General management strategies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because atrial fibrillation and flutter can be associated with structural heart disease in women of childbearing age, all women presenting with these arrhythmias should have a thorough clinical investigation, including a complete cardiac examination, an electrocardiogram, and a transthoracic echocardiogram. If an obvious provoking factor (eg, hyperthyroidism, alcohol abuse) is present [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/82\" class=\"abstract_t\">82</a>], treatment of the precipitant should be addressed.</p><p>We agree with the recommendations for pregnant women made in the 2006 American College of <span class=\"nowrap\">Cardiology/American</span> Heart <span class=\"nowrap\">Association/European</span> Society of Cardiology guidelines for the management of patients with atrial fibrillation [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/83\" class=\"abstract_t\">83</a>] and the European Society of Cardiology guidelines on the management of cardiovascular diseases during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14\" class=\"abstract_t\">14</a>] The following recommendations made in these guidelines are described below:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Direct current (DC) cardioversion is recommended in pregnant patients who become hemodynamically unstable due to atrial fibrillation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">Digoxin</a>, a beta blocker, or a non-dihydropyridine calcium channel antagonist is recommended to control the rate of ventricular response in pregnant patients with atrial fibrillation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Protection against thromboembolism is recommended throughout pregnancy for all patients with atrial fibrillation (except those women with very low thromboembolic risk). The CHADS2 score may be helpful to identify pregnant women who are at high risk for thromboembolic events and for whom antithrombotic therapy should be used. Many females of childbearing age are likely to have a CHADS2 score less than 2 with nonvalvular atrial fibrillation. Under these circumstances, therapy with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> may be appropriate.<br/><br/>Antithrombotic therapy with either anticoagulant or aspirin should be chosen on an individual basis. Low-dose aspirin and heparin can be used at all stages of pregnancy. Heparin needs to be discontinued prior to delivery. <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">Warfarin</a> is generally not used during pregnancy because of its potential teratogenicity. (See <a href=\"topic.htm?path=use-of-anticoagulants-during-pregnancy-and-postpartum\" class=\"medical medical_review\">&quot;Use of anticoagulants during pregnancy and postpartum&quot;</a>.) <br/><br/>Newer oral anticoagulants such as <a href=\"topic.htm?path=dabigatran-drug-information\" class=\"drug drug_general\">dabigatran</a>, <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a>, and <a href=\"topic.htm?path=apixaban-drug-information\" class=\"drug drug_general\">apixaban</a> are not recommended because of the potential for fetotoxicity at high doses and lack of safety data [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14\" class=\"abstract_t\">14</a>]. </p><p/><p class=\"headingAnchor\" id=\"H11407814\"><span class=\"h2\">Management of acute episodes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Episodes of atrial fibrillation and flutter that cause hemodynamic instability require emergent DC cardioversion [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14,83\" class=\"abstract_t\">14,83</a>]. Atrial fibrillation with rapid ventricular rates in women with pre-excitation is also best treated with DC cardioversion. For those women who are hemodynamically stable, pharmacological cardioversion can be attempted. (See <a href=\"#H11407933\" class=\"local\">'Electrical cardioversion'</a> below.)</p><p>For patients in whom immediate cardioversion is not needed, it is important to recognize that if an episode of AF lasts more than 48 hours, or is of unknown duration, a transesophageal echocardiogram should be performed or systemic anticoagulation maintained for three weeks prior to electrical or pharmacologic cardioversion. Systemic anticoagulation is needed for at least three weeks following cardioversion.</p><p>Pharmacological cardioversion can be achieved with class IA antiarrhythmic drugs (eg, <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a>, <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a>) (<a href=\"image.htm?imageKey=CARD%2F50716\" class=\"graphic graphic_table graphicRef50716 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/84\" class=\"abstract_t\">84</a>]. Quinidine has the longest record of use as an antiarrhythmic drug during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/58,85,86\" class=\"abstract_t\">58,85,86</a>], but in the current era it is no longer commonly used and can be difficult to obtain. If type IA antiarrhythmic drugs are used, they should be started in the hospital in order to monitor for proarrhythmia (see <a href=\"#H11407891\" class=\"local\">'Issues regarding antiarrhythmic drug treatment'</a> below). In women without structural heart disease, <a href=\"topic.htm?path=flecainide-drug-information\" class=\"drug drug_general\">flecainide</a> may be used in conjunction with an atrioventricular nodal blocking agent [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14\" class=\"abstract_t\">14</a>].</p><p>There is limited experience with <a href=\"topic.htm?path=ibutilide-drug-information\" class=\"drug drug_general\">ibutilide</a> used after the first trimester [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14,87,88\" class=\"abstract_t\">14,87,88</a>]. <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">Amiodarone</a> should only be used if other agents fail due to its potential fetotoxicity.</p><p class=\"headingAnchor\" id=\"H889561568\"><span class=\"h2\">Rhythm control versus rate control</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A major issue in the treatment of atrial fibrillation is the choice between rhythm control versus rate control. Randomized trials, particularly AFFIRM and RACE, have shown that both strategies are acceptable choices. However, the limitation of both trials is that they included mainly patients older than 65 years and therefore the results may not applicable to younger, pregnant women. During pregnancy, a rhythm control strategy is often preferred in those with new atrial fibrillation and in those with failure of rate control. (See <a href=\"topic.htm?path=rhythm-control-versus-rate-control-in-atrial-fibrillation\" class=\"medical medical_review\">&quot;Rhythm control versus rate control in atrial fibrillation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11407821\"><span class=\"h2\">Rate control</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If rhythm control cannot be achieved or is unlikely to be successful, then ventricular rate control can be instituted. <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">Digoxin</a>, beta blockers, or calcium channel blockers (eg, <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>) alone or in combination can be used to control the ventricular response rate [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/11,84,86\" class=\"abstract_t\">11,84,86</a>]. </p><p class=\"headingAnchor\" id=\"H25725799\"><span class=\"h2\">Rhythm control</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In women with pre-excitation, atrioventricular nodal blocking agents alone are contra-indicated because they can facilitate antegrade conduction over the accessory pathway, potentially leading to ventricular fibrillation. In these women, class IA (eg, <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a>, <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a>) and IC (eg, <a href=\"topic.htm?path=flecainide-drug-information\" class=\"drug drug_general\">flecainide</a>) antiarrhythmic drugs are the most effective at blocking conduction in the accessory pathway and preventing recurrences of tachycardia. (See <a href=\"#H11407891\" class=\"local\">'Issues regarding antiarrhythmic drug treatment'</a> below.)</p><p class=\"headingAnchor\" id=\"H11407828\"><span class=\"h2\">Anticoagulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pregnancy is a prothrombotic state and thresholds for initiating anticoagulation are often lower than in the nonpregnant state. There is no standardized anticoagulation regime during pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/89\" class=\"abstract_t\">89</a>], and the choice of anticoagulation should be tailored to the individual. Pregnant women with nonvalvular atrial fibrillation and low CHADS2 score, and those with lone atrial fibrillation, may not require therapy or they may be suitable candidates for therapy with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> (see <a href=\"topic.htm?path=overview-of-atrial-fibrillation#H439358969\" class=\"medical medical_review\">&quot;Overview of atrial fibrillation&quot;, section on 'Lone AF'</a>). For women with higher thrombotic risk, the preferred anticoagulant is low-molecular weight heparin. <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">Warfarin</a> is reserved for women with more complex risk factors, such as some with mechanical heart valves. Novel oral anticoagulants are not recommended because of potential fetal toxicity at high doses [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H11407891\"><span class=\"h1\">ISSUES REGARDING ANTIARRHYTHMIC DRUG TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The rate of placental passage of any drug is dependent on lipid solubility, molecular weight, protein binding, ionization, fetal and placental blood flow, and pH of maternal and fetal fluids [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13,90\" class=\"abstract_t\">13,90</a>]. Nonionized, nonprotein bound, lipid soluble drugs with molecular weight below 600 Daltons freely cross the placenta [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/91\" class=\"abstract_t\">91</a>], while high molecular weight drugs are not transported in significant amounts. Almost all antiarrhythmic drugs cross the placenta. Fetal tissues begin to differentiate during the period of organogenesis (gestational weeks 5 to 10) and are most susceptible to the effects of teratogens at that time. The major concern with antiarrhythmic drugs taken during the second and third trimesters are potential adverse effects on fetal growth and development, drug-related side effects in the neonate, risk of proarrhythmia, and possible effects on uterine contractility [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13\" class=\"abstract_t\">13</a>]. </p><p class=\"headingAnchor\" id=\"H11407898\"><span class=\"h2\">Safety during pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Safety profiles of antiarrhythmic drugs are drawn from case reports, case series, registry data, and case control and cohort studies of pregnant women treated with these drugs, alone or with other agents, and for a variety of indications, including hypertension, maternal or fetal arrhythmias, and a wide spectrum of underlying medical disorders, which could confound findings [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/92\" class=\"abstract_t\">92</a>]. There are no data from large well-designed randomized trials on which to base a recommendation for use of one drug over another. Data regarding both comparative efficacy in improving maternal outcome and fetal safety are inadequate for almost all antiarrhythmic drugs.</p><p>Information related to the toxicity and teratogenicity of medications in pregnant women must be interpreted in light of the background risk of adverse pregnancy outcomes in any pregnant woman. Major birth defects are defined as events of medical, surgical, or cosmetic significance. It is estimated that the prevalence of major birth defects is 2 to 4 percent among live born infants, and in utero growth restriction occurs in 3 to 10 percent of pregnancies, depending on the definition used. Intrauterine growth restriction can be related to in utero drug exposure, the mother's disease, other drug therapy, or a combination of these and other factors (eg, intrinsic fetal or placental factors).</p><p>Since 1975, the United States Food and Drug Administration (FDA) has assigned pregnancy risk factors to all drugs available in the United States. Information on the use of specific drugs in pregnancy, including the FDA risk category and pregnancy implications, is available in the UpToDate drug database. Specific information on the fetal and neonatal risks of maternal drug ingestion during pregnancy and lactation are also available from several resources, including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.perinatology.com/exposures/druglist.htm&amp;token=jc3SKr4sVgyEWB4Td3cb57yGHj2Qi19M4OPzpmAAijOuo4jqvraRneIps79GZ/8NQr2IEfOFnfnIDmQ2klTUJQ==&amp;TOPIC_ID=13600\" target=\"_blank\" class=\"external\">www.perinatology.com/exposures/druglist.htm</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.motherisk.org/women/drugs.jsp&amp;token=GAhe3OOzVjSUOiFPkwJcldytY9PliMbfrMlXf7kglFVJmMmIxwldFznElKJxFMbDrwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=13600\" target=\"_blank\" class=\"external\">www.motherisk.org/women/drugs.jsp</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://depts.washington.edu/terisweb/teris/&amp;token=zabqurEZHkal7+CWLysn7JqkjgD+nXFm1iomIGbekQED6jTfsJmvowdVHauceaTm&amp;TOPIC_ID=13600\" target=\"_blank\" class=\"external\">http://depts.washington.edu/terisweb/teris/</a> (requires subscription)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.reprotox.org/&amp;token=FCLVABAT7XxGqlfYUn1Ecl6G+DMwsHd8tp1W16P3UJmvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=13600\" target=\"_blank\" class=\"external\">www.reprotox.org/</a> (requires subscription)</p><p/><p>The following table provides a brief synopsis of pregnancy and breastfeeding implications for the drugs discussed in this topic (<a href=\"image.htm?imageKey=CARD%2F50716\" class=\"graphic graphic_table graphicRef50716 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H11407912\"><span class=\"h2\">Pharmacokinetic changes during pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Physiological changes during pregnancy may alter the absorption, excretion and effective plasma concentration of all antiarrhythmic drugs [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13\" class=\"abstract_t\">13</a>]. Increased intravascular volumes during pregnancy may require an increase in loading dose [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/90\" class=\"abstract_t\">90</a>]. Gastrointestinal absorption of drugs may be altered by changes in gastric secretion and intestinal motility [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13,90,93\" class=\"abstract_t\">13,90,93</a>]. Increase in renal blood flow and progesterone-induced increase of hepatic metabolism may augment drug clearance [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/94,95\" class=\"abstract_t\">94,95</a>]. Finally, decreased serum protein concentrations may reduce protein binding [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/90\" class=\"abstract_t\">90</a>], decreasing the total drug concentration and leading to greater fluctuation in unbound drug concentration. These pharmacokinetic changes may explain why pregnant women previously stable on antiarrhythmic therapy have breakthrough arrhythmias. Because of intra-individual variability in the abovementioned factors, drug dosage should be optimized on an individual basis with monitoring of clinical response.</p><p class=\"headingAnchor\" id=\"H11407919\"><span class=\"h2\">Breast feeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, drugs that are most likely to be transferred from maternal plasma to milk have the following characteristics: nonionized, nonprotein bound, low molecular weight, high lipid solubility, and high pH. In addition to drug transfer, drug clearance in the setting of a neonate's immature renal and hepatic function also determines whether a drug <span class=\"nowrap\">and/or</span> its metabolites reach therapeutic or toxic levels in the infant.</p><p>The LactMed database, produced by the National Library of Medicine, provides monographs on many prescription and over-the-counter medications. The database is available free of charge at <a href=\"http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT&amp;token=uFbFTjFpzLQOPfYhN9e/pcLVYu7Q3qIInrYxROT/7X+hm8Hcgw0kPpSotrHmeHTVRoZX2HY0Ag9EJRG1fe3/8Q==&amp;TOPIC_ID=13600\" target=\"_blank\" class=\"external\">http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT</a>. The UpToDate drug database also provides information on lactation and breastfeeding implications for all drugs in the database.</p><p>The following table provides a brief synopsis of pregnancy and breastfeeding implications for drugs discussed in this topic (<a href=\"image.htm?imageKey=CARD%2F50716\" class=\"graphic graphic_table graphicRef50716 \">table 1</a>). </p><p class=\"headingAnchor\" id=\"H11407926\"><span class=\"h1\">ISSUES REGARDING NON-PHARMACOLOGIC TREATMENT</span></p><p class=\"headingAnchor\" id=\"H11407933\"><span class=\"h2\">Electrical cardioversion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Emergent or elective electrical cardioversion can be performed at all stages of pregnancy [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13,44,45,85,96-99\" class=\"abstract_t\">13,44,45,85,96-99</a>], and should be used for any sustained arrhythmia with hemodynamic compromise and can be considered for drug-refractory arrhythmias. Electrical cardioversion does not result in compromise of blood flow to the fetus [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/100\" class=\"abstract_t\">100</a>]. While there is a theoretical risk of inducing an arrhythmia in the fetus, this risk is very small due to the high fibrillation threshold and small amount of energy reaching the fetus [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13,85,101\" class=\"abstract_t\">13,85,101</a>]. Nonetheless, fetal rhythm monitoring is recommended because of reported cases of emergency cesarean delivery due to fetal arrhythmias [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/102\" class=\"abstract_t\">102</a>]. In the third trimester, some physicians prefer to perform electrical cardioversion under general anesthesia and intubation, considering the more difficult airway and increased risk of gastric aspiration during pregnancy.</p><p class=\"headingAnchor\" id=\"H11407940\"><span class=\"h2\">Radiofrequency catheter ablation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In non-pregnant patients, more definitive treatment of atrial fibrillation, atrial flutter, and other arrhythmias can be accomplished with radiofrequency catheter ablation [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/103\" class=\"abstract_t\">103</a>]. (See <a href=\"topic.htm?path=overview-of-catheter-ablation-of-cardiac-arrhythmias#H1\" class=\"medical medical_review\">&quot;Overview of catheter ablation of cardiac arrhythmias&quot;, section on 'Introduction'</a>.)</p><p>Consideration should be given to ablation prior to pregnancy in patients with symptomatic arrhythmias not well controlled with pharmacologic therapy. Ablation of atrial flutter and other arrhythmias is generally avoided during pregnancy given the need for fluoroscopy. For those experiencing new onset of arrhythmias suitable for radiofrequency ablation, or worsening of existing arrhythmias during pregnancy, ablation is generally delayed until after delivery.</p><p>Experience with radiofrequency catheter ablation during pregnancy has been limited to cases of supraventricular tachycardia [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/65,69,104-109\" class=\"abstract_t\">65,69,104-109</a>]. These procedures are generally not performed during pregnancy, mainly due to concerns of ionizing radiation exposure to the fetus. However, in rare cases, women with severe and drug-resistant arrhythmias during pregnancy may be considered for an ablation procedure. The risk of radiation exposure for the fetus during a typical ablation is small (&lt;1 mGy at all periods of gestation), and is mainly attributable to scatter from the thorax of the mother [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/110\" class=\"abstract_t\">110</a>]. (See <a href=\"topic.htm?path=diagnostic-imaging-procedures-during-pregnancy\" class=\"medical medical_review\">&quot;Diagnostic imaging procedures during pregnancy&quot;</a>.) </p><p>Cases of successful ablation of atrial tachycardia using intracardiac echocardiography and electro-anatomic mapping without fluoroscopy have been reported [<a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/111,112\" class=\"abstract_t\">111,112</a>].<br/></p><p class=\"headingAnchor\" id=\"H587892907\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-atrial-fibrillation\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Atrial fibrillation&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-arrhythmias-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Arrhythmias in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H889561628\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. (See <a href=\"#H11407716\" class=\"local\">'Palpitations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Since cardiac arrhythmias are frequently associated with structural heart disease, any woman who presents with an arrhythmia during pregnancy should undergo clinical evaluation for structural heart disease (including an electrocardiogram and a transthoracic echocardiogram). (See <a href=\"#H11407807\" class=\"local\">'General management strategies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common arrhythmia in women with structurally normal hearts is paroxysmal supraventricular tachycardia, including atrioventricular (AV)-nodal reentrant tachycardia and AV reciprocating tachycardia. Management of paroxysmal supraventricular tachycardia can be accomplished with a number of AV-nodal blocking agents. If hemodynamic compromise is evident, direct-current cardioversion should be performed. (See <a href=\"#H11407744\" class=\"local\">'Paroxysmal supraventricular tachycardia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atrial fibrillation and flutter during pregnancy are less common than paroxysmal supraventricular tachycardia, and often occur in women with structural heart disease. (See <a href=\"#H11407793\" class=\"local\">'Atrial fibrillation and flutter'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In pregnant women with atrial fibrillation, a rhythm control strategy is preferred in those with a new onset atrial fibrillation and in those with failure of rate control. If rhythm control cannot be achieved or is unlikely to be successful, then ventricular rate control can be instituted. (See <a href=\"#H889561568\" class=\"local\">'Rhythm control versus rate control'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pregnancy is a prothrombotic state and thresholds for initiating anticoagulation are often lower than in the nonpregnant state. There is no standardized anticoagulation regime during pregnancy and the choice of anticoagulation should be tailored to the individual. (See <a href=\"#H11407828\" class=\"local\">'Anticoagulation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Information on the use of specific antiarrhythmic drugs in pregnancy, including the United States Food and Drug Administration risk category and pregnancy implications, is available in the UpToDate drug database. (See <a href=\"#H11407891\" class=\"local\">'Issues regarding antiarrhythmic drug treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/1\" class=\"nounderline abstract_t\">Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/2\" class=\"nounderline abstract_t\">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/3\" class=\"nounderline abstract_t\">Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010; 31:2124.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/4\" class=\"nounderline abstract_t\">Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 1995; 76:675.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/5\" class=\"nounderline abstract_t\">Doig JC, McComb JM, Reid DS. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 67:266.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/6\" class=\"nounderline abstract_t\">Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/7\" class=\"nounderline abstract_t\">Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997; 96:2789.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/8\" class=\"nounderline abstract_t\">Drenthen W, Pieper PG, Ploeg M, et al. Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. Eur Heart J 2005; 26:2588.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/9\" class=\"nounderline abstract_t\">Drenthen W, Pieper PG, van der Tuuk K, et al. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. Eur Heart J 2005; 26:2581.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/10\" class=\"nounderline abstract_t\">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Pregnancy and delivery in women after Fontan palliation. Heart 2006; 92:1290.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/11\" class=\"nounderline abstract_t\">Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/12\" class=\"nounderline abstract_t\">Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf 1999; 20:85.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/13\" class=\"nounderline abstract_t\">Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36:137.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/14\" class=\"nounderline abstract_t\">European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.</a></li><li class=\"breakAll\">Silversides CK, Colman JM. Physiological changes in pregnancy. In: Heart disease in pregnancy, 2nd ed, Oakley C, Warnes CA (Eds), Blackwell Publishing, Malden 2007. p.6.</li><li class=\"breakAll\">Elkayam U, Gleicher N. Hemodynamics and cardiac function during normal pregnancy and puerperium. In: Cardiac problems in pregnancy, 3rd ed, Elkayam U, Gleicher N (Eds), Wiley-Liss, New York 1998. p.3.</li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/17\" class=\"nounderline abstract_t\">Katz R, Karliner JS, Resnik R. Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects. Circulation 1978; 58:434.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/18\" class=\"nounderline abstract_t\">Rubler S, Damani PM, Pinto ER. Cardiac size and performance during pregnancy estimated with echocardiography. Am J Cardiol 1977; 40:534.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/19\" class=\"nounderline abstract_t\">Liebson PR, Mann LI, Evans MI, et al. Cardiac performance during pregnancy: serial evaluation using external systolic time intervals. Am J Obstet Gynecol 1975; 122:1.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/20\" class=\"nounderline abstract_t\">Campos O. Doppler Echocardiography During Pregnancy: Physiological and Abnormal Findings. Echocardiography 1996; 13:135.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/21\" class=\"nounderline abstract_t\">Franz MR, Cima R, Wang D, et al. Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias. Circulation 1992; 86:968.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/22\" class=\"nounderline abstract_t\">Wang Y, Joyner RW, Wagner MB, et al. Stretch-activated channel activation promotes early afterdepolarizations in rat ventricular myocytes under oxidative stress. Am J Physiol Heart Circ Physiol 2009; 296:H1227.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/23\" class=\"nounderline abstract_t\">Ninio DM, Saint DA. The role of stretch-activated channels in atrial fibrillation and the impact of intracellular acidosis. Prog Biophys Mol Biol 2008; 97:401.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/24\" class=\"nounderline abstract_t\">Kamkin A, Kiseleva I, Isenberg G. Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 2000; 48:409.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/25\" class=\"nounderline abstract_t\">Soliman EZ, Elsalam MA, Li Y. The relationship between high resting heart rate and ventricular arrhythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording. Europace 2010; 12:261.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/26\" class=\"nounderline abstract_t\">Zuspan FP. Catecholamines. Their role in pregnancy and the development of pregnancy-induced hypertension. J Reprod Med 1979; 23:143.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/27\" class=\"nounderline abstract_t\">Natrajan PG, McGarrigle HH, Lawrence DM, Lachelin GC. Plasma noradrenaline and adrenaline levels in normal pregnancy and in pregnancy-induced hypertension. Br J Obstet Gynaecol 1982; 89:1041.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/28\" class=\"nounderline abstract_t\">Whittaker PG, Gerrard J, Lind T. Catecholamine responses to changes in posture during human pregnancy. Br J Obstet Gynaecol 1985; 92:586.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/29\" class=\"nounderline abstract_t\">Barron WM, Mujais SK, Zinaman M, et al. Plasma catecholamine responses to physiologic stimuli in normal human pregnancy. Am J Obstet Gynecol 1986; 154:80.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/30\" class=\"nounderline abstract_t\">Ramsay MM, Broughton Pipkin F, Rubin PC. Pressor, heart rate and plasma catecholamine responses to noradrenaline in pregnant and nonpregnant women. Br J Obstet Gynaecol 1993; 100:170.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/31\" class=\"nounderline abstract_t\">Roberts JM, Insel PA, Goldfien A. Regulation of myometrial adrenoreceptors and adrenergic response by sex steroids. Mol Pharmacol 1981; 20:52.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/32\" class=\"nounderline abstract_t\">Priori SG, Mantica M, Schwartz PJ. Delayed afterdepolarizations elicited in vivo by left stellate ganglion stimulation. Circulation 1988; 78:178.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/33\" class=\"nounderline abstract_t\">Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol 1997; 79:1061.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/34\" class=\"nounderline abstract_t\">Li JM, Nguyen C, Joglar JA, et al. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol 2008; 31:538.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/35\" class=\"nounderline abstract_t\">Tawam M, Levine J, Mendelson M, et al. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 1993; 72:838.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/36\" class=\"nounderline abstract_t\">Smith WM, Gallagher JJ, Kerr CR, et al. The electrophysiologic basis and management of symptomatic recurrent tachycardia in patients with Ebstein's anomaly of the tricuspid valve. Am J Cardiol 1982; 49:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/37\" class=\"nounderline abstract_t\">MENDELSON CL. Disorders of the heartbeat during pregnancy. Am J Obstet Gynecol 1956; 72:1268.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/38\" class=\"nounderline abstract_t\">Gleicher N, Meller J, Sandler RZ, Sullum S. Wolff-Parkinson-White syndrome in pregnancy. Obstet Gynecol 1981; 58:748.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/39\" class=\"nounderline abstract_t\">Widerhorn J, Widerhorn AL, Rahimtoola SH, Elkayam U. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am Heart J 1992; 123:796.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/40\" class=\"nounderline abstract_t\">Kounis NG, Zavras GM, Papadaki PJ, et al. Pregnancy-induced increase of supraventricular arrhythmias in Wolff-Parkinson-White syndrome. Clin Cardiol 1995; 18:137.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/41\" class=\"nounderline abstract_t\">SZEKELY P, SNAITH L. Paroxysmal tachycardia in pregnancy. Br Heart J 1953; 15:195.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/42\" class=\"nounderline abstract_t\">Murphy JJ, Hutchon DJ. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 68:342.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/43\" class=\"nounderline abstract_t\">Treakle K, Kostic B, Hulkower S. Supraventricular tachycardia resistant to treatment in a pregnant woman. J Fam Pract 1992; 35:581.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/44\" class=\"nounderline abstract_t\">Schroeder JS, Harrison DC. Repeated cardioversion during pregnancy. Treatment of refractory paroxysmal atrial tachycardia during 3 successive pregnancies. Am J Cardiol 1971; 27:445.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/45\" class=\"nounderline abstract_t\">Hubbard WN, Jenkins BA, Ward DE. Persistent atrial tachycardia in pregnancy. Br Med J (Clin Res Ed) 1983; 287:327.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/46\" class=\"nounderline abstract_t\">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016; 67:e27.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/47\" class=\"nounderline abstract_t\">Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol 1995; 75:521.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/48\" class=\"nounderline abstract_t\">Harrison JK, Greenfield RA, Wharton JM. Acute termination of supraventricular tachycardia by adenosine during pregnancy. Am Heart J 1992; 123:1386.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/49\" class=\"nounderline abstract_t\">Podolsky SM, Varon J. Adenosine use during pregnancy. Ann Emerg Med 1991; 20:1027.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/50\" class=\"nounderline abstract_t\">Mason BA, Ricci-Goodman J, Koos BJ. Adenosine in the treatment of maternal paroxysmal supraventricular tachycardia. Obstet Gynecol 1992; 80:478.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/51\" class=\"nounderline abstract_t\">Afridi I, Moise KJ Jr, Rokey R. Termination of supraventricular tachycardia with intravenous adenosine in a pregnant woman with Wolff-Parkinson-White syndrome. Obstet Gynecol 1992; 80:481.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/52\" class=\"nounderline abstract_t\">Leffler S, Johnson DR. Adenosine use in pregnancy: lack of effect on fetal heart rate. Am J Emerg Med 1992; 10:548.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/53\" class=\"nounderline abstract_t\">DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med 1990; 113:104.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/54\" class=\"nounderline abstract_t\">Wheeler CP, Yudilevich DL. Transport and metabolism of adenosine in the perfused guinea-pig placenta. J Physiol 1988; 405:511.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/55\" class=\"nounderline abstract_t\">Jaqueti J, Martinez-Hern&aacute;ndez D, Hern&aacute;ndez-Garcia R, et al. Adenosine deaminase in pregnancy serum. Clin Chem 1990; 36:2144.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/56\" class=\"nounderline abstract_t\">Mariani PJ. Pharmacotherapy of pregnancy--related SVT. Ann Emerg Med 1992; 21:229.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/57\" class=\"nounderline abstract_t\">Byerly WG, Hartmann A, Foster DE, Tannenbaum AK. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med 1991; 20:552.</a></li><li class=\"breakAll\">Briggs GC, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008.</li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/59\" class=\"nounderline abstract_t\">Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol 1984; 54:1138.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/60\" class=\"nounderline abstract_t\">Rubin PC. Beta blockers in pregnancy. Br J Obstet Gynaecol 1987; 94:292.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/61\" class=\"nounderline abstract_t\">Blake S, MacDonald D. The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment. Br J Obstet Gynaecol 1991; 98:244.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/62\" class=\"nounderline abstract_t\">Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301:587.</a></li><li class=\"breakAll\">Magee, LA, Duley, L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2000:CD002863.</li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/64\" class=\"nounderline abstract_t\">Lip GY, Beevers M, Churchill D, et al. Effect of atenolol on birth weight. Am J Cardiol 1997; 79:1436.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/65\" class=\"nounderline abstract_t\">Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol 2010; 21:877.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/66\" class=\"nounderline abstract_t\">Robards GJ, Saunders DM, Donnelly GL. Refractory supraventricular tachycardia complicating pregnancy. Med J Aust 1973; 2:278.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/67\" class=\"nounderline abstract_t\">Cruz FE, Cheriex EC, Smeets JL, et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol 1990; 16:739.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/68\" class=\"nounderline abstract_t\">Haines DE, DiMarco JP. Sustained intraatrial reentrant tachycardia: clinical, electrocardiographic and electrophysiologic characteristics and long-term follow-up. J Am Coll Cardiol 1990; 15:1345.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/69\" class=\"nounderline abstract_t\">Pagad SV, Barmade AB, Toal SC, et al. 'Rescue' radiofrequency ablation for atrial tachycardia presenting as cardiomyopathy in pregnancy. Indian Heart J 2004; 56:245.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/70\" class=\"nounderline abstract_t\">Gowda RM, Punukollu G, Khan IA, et al. Lone atrial fibrillation during pregnancy. Int J Cardiol 2003; 88:123.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/71\" class=\"nounderline abstract_t\">Kuczkowski KM. New onset transient lone atrial fibrillation in a healthy parturient: d&eacute;j&agrave; vu. Int J Cardiol 2004; 97:339.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/72\" class=\"nounderline abstract_t\">McCans JL, Wenger NK. Problems in management of the pregnant patient with rheumatic heart disease and valve prosthesis. South Med J 1976; 69:1007.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/73\" class=\"nounderline abstract_t\">Bryg RJ, Gordon PR, Kudesia VS, Bhatia RK. Effect of pregnancy on pressure gradient in mitral stenosis. Am J Cardiol 1989; 63:384.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/74\" class=\"nounderline abstract_t\">Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:1864.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/75\" class=\"nounderline abstract_t\">Homans DC. Peripartum cardiomyopathy. N Engl J Med 1985; 312:1432.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/76\" class=\"nounderline abstract_t\">Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation 2007; 115:534.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/77\" class=\"nounderline abstract_t\">Tateno S, Niwa K, Nakazawa M, et al. Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study. Circ J 2003; 67:992.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/78\" class=\"nounderline abstract_t\">Whittemore R, Hobbins JC, Engle MA. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol 1982; 50:641.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/79\" class=\"nounderline abstract_t\">Balci A, Drenthen W, Mulder BJ, et al. Pregnancy in women with corrected tetralogy of Fallot: occurrence and predictors of adverse events. Am Heart J 2011; 161:307.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/80\" class=\"nounderline abstract_t\">Wessel HU, Benson DW Jr, Braunlin EA, et al. Exercise response before and after termination of atrial tachycardia after congenital heart disease surgery. Circulation 1989; 80:106.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/81\" class=\"nounderline abstract_t\">SZEKELY P, SNAITH L. Atrial fibrillation and pregnancy. Br Med J 1961; 1:1407.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/82\" class=\"nounderline abstract_t\">Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a correctable cause of &quot;idiopathic&quot; atrial fibrillation. Am J Cardiol 1979; 44:9.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/83\" class=\"nounderline abstract_t\">Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/84\" class=\"nounderline abstract_t\">European Heart Rhythm Association, Heart Rhythm Society, Fuster V, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48:854.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/85\" class=\"nounderline abstract_t\">Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995; 130:871.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/86\" class=\"nounderline abstract_t\">Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J 2001; 22:458.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/87\" class=\"nounderline abstract_t\">Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol 2007; 18:545.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/88\" class=\"nounderline abstract_t\">Burkart TA, Kron J, Miles WM, et al. Successful termination of atrial flutter by ibutilide during pregnancy. Pacing Clin Electrophysiol 2007; 30:283.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/89\" class=\"nounderline abstract_t\">Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24:761.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/90\" class=\"nounderline abstract_t\">Mitani GM, Steinberg I, Lien EJ, et al. The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet 1987; 12:253.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/91\" class=\"nounderline abstract_t\">Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43:487.</a></li><li class=\"breakAll\">Leung CY, Brodsky MA. Cardiac arrhythmias and pregnancy. In: Cardiac problems in pregnancy, 3rd ed, Elkayam U, Gleicher N (Eds), Wiley-Liss, New York 1998. p.155.</li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/93\" class=\"nounderline abstract_t\">Rotmensch HH, Rotmensch S, Elkayam U. Management of cardiac arrhythmias during pregnancy. Current concepts. Drugs 1987; 33:623.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/94\" class=\"nounderline abstract_t\">Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol 1981; 88:1.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/95\" class=\"nounderline abstract_t\">Krauer B, Krauer F. Drug kinetics in pregnancy. Clin Pharmacokinet 1977; 2:167.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/96\" class=\"nounderline abstract_t\">Ueland K, McAnulty JH, Ueland FR, Metcalfe J. Special considerations in the use of cardiovascular drugs. Clin Obstet Gynecol 1981; 24:809.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/97\" class=\"nounderline abstract_t\">VOGEL JH, PRYOR R, BLOUNT SG Jr. DIRECT-CURRENT DEFIBRILLATION DURING PREGNANCY. JAMA 1965; 193:970.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/98\" class=\"nounderline abstract_t\">Lee RV, Rodgers BD, White LM, Harvey RC. Cardiopulmonary resuscitation of pregnant women. Am J Med 1986; 81:311.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/99\" class=\"nounderline abstract_t\">Russell RO Jr. Paroxysmal ventricular tachycardia associated with pregnancy. Ala J Med Sci 1969; 6:111.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/100\" class=\"nounderline abstract_t\">Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006; 126:268.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/101\" class=\"nounderline abstract_t\">DeSilva RA, Graboys TB, Podrid PJ, Lown B. Cardioversion and defibrillation. Am Heart J 1980; 100:881.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/102\" class=\"nounderline abstract_t\">Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 2002; 109:1406.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/103\" class=\"nounderline abstract_t\">Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009; 104:671.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/104\" class=\"nounderline abstract_t\">Bongiorni MG, Di Cori A, Soldati E, et al. Radiofrequency catheter ablation of atrioventricular nodal reciprocating tachycardia using intracardiac echocardiography in pregnancy. Europace 2008; 10:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/105\" class=\"nounderline abstract_t\">Risius T, Mortensen K, Meinertz T, Willems S. Cluster of multiple atrial tachycardias limited to pregnancy after radiofrequency ablation following senning operation. Int J Cardiol 2008; 123:e48.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/106\" class=\"nounderline abstract_t\">Kanjwal Y, Kosinski D, Kanj M, et al. Successful radiofrequency catheter ablation of left lateral accessory pathway using transseptal approach during pregnancy. J Interv Card Electrophysiol 2005; 13:239.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/107\" class=\"nounderline abstract_t\">Bombelli F, Lagona F, Salvati A, et al. Radiofrequency catheter ablation in drug refractory maternal supraventricular tachycardias in advanced pregnancy. Obstet Gynecol 2003; 102:1171.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/108\" class=\"nounderline abstract_t\">Dom&iacute;nguez A, Iturralde P, Hermosillo AG, et al. Successful radiofrequency ablation of an accessory pathway during pregnancy. Pacing Clin Electrophysiol 1999; 22:131.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/109\" class=\"nounderline abstract_t\">Berruezo A, D&iacute;ez GR, Berne P, et al. Low exposure radiation with conventional guided radiofrequency catheter ablation in pregnant women. Pacing Clin Electrophysiol 2007; 30:1299.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/110\" class=\"nounderline abstract_t\">Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation 2001; 104:893.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/111\" class=\"nounderline abstract_t\">Ferguson JD, Helms A, Mangrum JM, DiMarco JP. Ablation of incessant left atrial tachycardia without fluoroscopy in a pregnant woman. J Cardiovasc Electrophysiol 2011; 22:346.</a></li><li><a href=\"https://www.uptodate.com/contents/supraventricular-arrhythmias-during-pregnancy/abstract/112\" class=\"nounderline abstract_t\">Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol 2010; 21:877.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13600 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H889561628\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H11407702\" id=\"outline-link-H11407702\">INTRODUCTION</a></li><li><a href=\"#H11407709\" id=\"outline-link-H11407709\">MECHANISM OF ARRHYTHMOGENESIS IN PREGNANCY</a></li><li><a href=\"#H11407716\" id=\"outline-link-H11407716\">PALPITATIONS</a></li><li><a href=\"#H11407723\" id=\"outline-link-H11407723\">ATRIAL PREMATURE BEATS</a><ul><li><a href=\"#H11407730\" id=\"outline-link-H11407730\">Clinical presentation</a></li><li><a href=\"#H11407737\" id=\"outline-link-H11407737\">Management</a></li></ul></li><li><a href=\"#H11407744\" id=\"outline-link-H11407744\">PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA</a><ul><li><a href=\"#H11407751\" id=\"outline-link-H11407751\">Clinical presentation</a></li><li><a href=\"#H2955272064\" id=\"outline-link-H2955272064\">Management</a></li><li><a href=\"#H11407758\" id=\"outline-link-H11407758\">Management of acute episodes</a></li><li><a href=\"#H11407765\" id=\"outline-link-H11407765\">Prophylactic pharmacologic therapy</a></li></ul></li><li><a href=\"#H11407772\" id=\"outline-link-H11407772\">FOCAL ATRIAL TACHYCARDIA</a><ul><li><a href=\"#H11407779\" id=\"outline-link-H11407779\">Clinical presentation</a></li><li><a href=\"#H11407786\" id=\"outline-link-H11407786\">Diagnosis and management</a></li></ul></li><li><a href=\"#H11407793\" id=\"outline-link-H11407793\">ATRIAL FIBRILLATION AND FLUTTER</a><ul><li><a href=\"#H11407800\" id=\"outline-link-H11407800\">Clinical presentation</a></li><li><a href=\"#H11407807\" id=\"outline-link-H11407807\">General management strategies</a></li><li><a href=\"#H11407814\" id=\"outline-link-H11407814\">Management of acute episodes</a></li><li><a href=\"#H889561568\" id=\"outline-link-H889561568\">Rhythm control versus rate control</a></li><li><a href=\"#H11407821\" id=\"outline-link-H11407821\">Rate control</a></li><li><a href=\"#H25725799\" id=\"outline-link-H25725799\">Rhythm control</a></li><li><a href=\"#H11407828\" id=\"outline-link-H11407828\">Anticoagulation</a></li></ul></li><li><a href=\"#H11407891\" id=\"outline-link-H11407891\">ISSUES REGARDING ANTIARRHYTHMIC DRUG TREATMENT</a><ul><li><a href=\"#H11407898\" id=\"outline-link-H11407898\">Safety during pregnancy</a></li><li><a href=\"#H11407912\" id=\"outline-link-H11407912\">Pharmacokinetic changes during pregnancy</a></li><li><a href=\"#H11407919\" id=\"outline-link-H11407919\">Breast feeding</a></li></ul></li><li><a href=\"#H11407926\" id=\"outline-link-H11407926\">ISSUES REGARDING NON-PHARMACOLOGIC TREATMENT</a><ul><li><a href=\"#H11407933\" id=\"outline-link-H11407933\">Electrical cardioversion</a></li><li><a href=\"#H11407940\" id=\"outline-link-H11407940\">Radiofrequency catheter ablation</a></li></ul></li><li><a href=\"#H587892907\" id=\"outline-link-H587892907\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H889561628\" id=\"outline-link-H889561628\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/13600|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/61986\" class=\"graphic graphic_figure\">- Prevalence arrhythmias pregnancy congenital heart disease</a></li></ul></li><li><div id=\"CARD/13600|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/50716\" class=\"graphic graphic_table\">- Antiarrhythmic drugs in pregnancy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=arrhythmia-induced-cardiomyopathy\" class=\"medical medical_review\">Arrhythmia-induced cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization\" class=\"medical medical_review\">Atrial fibrillation: Anticoagulant therapy to prevent embolization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrioventricular-nodal-reentrant-tachycardia\" class=\"medical medical_review\">Atrioventricular nodal reentrant tachycardia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=basic-principles-and-technique-of-electrical-cardioversion-and-defibrillation\" class=\"medical medical_review\">Basic principles and technique of electrical cardioversion and defibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardioversion-for-specific-arrhythmias\" class=\"medical medical_review\">Cardioversion for specific arrhythmias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-rheumatic-mitral-stenosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of rheumatic mitral stenosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-evaluation-of-narrow-qrs-complex-tachycardias\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-imaging-procedures-during-pregnancy\" class=\"medical medical_review\">Diagnostic imaging procedures during pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ecg-tutorial-atrial-and-atrioventricular-nodal-supraventricular-arrhythmias\" class=\"medical medical_review\">ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-and-risk-factors-for-atrial-fibrillation\" class=\"medical medical_review\">Epidemiology of and risk factors for atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=focal-atrial-tachycardia\" class=\"medical medical_review\">Focal atrial tachycardia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maternal-adaptations-to-pregnancy-cardiovascular-and-hemodynamic-changes\" class=\"medical medical_review\">Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maternal-conduction-disorders-and-bradycardia-during-pregnancy\" class=\"medical medical_review\">Maternal conduction disorders and bradycardia during pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-atrial-fibrillation\" class=\"medical medical_review\">Overview of atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-atrial-flutter\" class=\"medical medical_review\">Overview of atrial flutter</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-catheter-ablation-of-cardiac-arrhythmias\" class=\"medical medical_review\">Overview of catheter ablation of cardiac arrhythmias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-palpitations-in-adults\" class=\"medical medical_review\">Overview of palpitations in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rhythm-control-versus-rate-control-in-atrial-fibrillation\" class=\"medical medical_review\">Rhythm control versus rate control in atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-arrhythmias-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Arrhythmias in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-atrial-fibrillation\" class=\"medical medical_society_guidelines\">Society guideline links: Atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=supraventricular-premature-beats\" class=\"medical medical_review\">Supraventricular premature beats</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-anticoagulants-during-pregnancy-and-postpartum\" class=\"medical medical_review\">Use of anticoagulants during pregnancy and postpartum</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ventricular-arrhythmias-during-pregnancy\" class=\"medical medical_review\">Ventricular arrhythmias during pregnancy</a></li></ul></div></div>","javascript":null}